Atomo Diagnostics secures significant order for HIV Self-Tests

Atomo Diagnostics Limited (ASX: $AT1) has secured purchase orders worth approximately AUD $970,000 for HIV Self-Tests, manufactured under the Mylan brand, for supply to Low- and Middle-Income Countries (LMICs). The orders are for manufacture during the second half of FY24, and the company considers the revenue from these orders to be material.

Executive Commentary on Securing Purchase Orders

We have seen growing demand during FY24 for the Atomo HIV Self-Test here in Australia as well as across branded versions supplied to international markets. Following significant increases in sales to Europe and in Australia, it is good to now see emergent demand across LMIC markets from our global health partner for HIV testing, Viatris.

Summary of Atomo Diagnostics Announcement

Atomo Diagnostics (ASX: $AT1) has secured significant purchase orders for HIV Self-Tests, indicating growing demand for its products in international markets, particularly in LMIC territories. The company's unique patented devices have simplified testing procedures, enhancing usability and improving reliability across rapid point-of-care (POC) and at-home testing applications. With supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation, and female health, Atomo is well-positioned to continue its growth trajectory. The securing of these orders reflects the company's commitment to addressing global health challenges and expanding its presence in LMIC markets, contributing to its corporate strategy and long-term goals.